205 related articles for article (PubMed ID: 23079010)
1. Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo.
Yu JA; Mauchley D; Li H; Meng X; Nemenoff RA; Fullerton DA; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1185-91. PubMed ID: 23079010
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of S100A7 reduces lung squamous cell carcinoma cell growth in vitro and in vivo.
Liu G; Wu Q; Liu G; Song X; Zhang J
Int J Clin Exp Pathol; 2014; 7(11):8279-89. PubMed ID: 25550886
[TBL] [Abstract][Full Text] [Related]
3. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
[TBL] [Abstract][Full Text] [Related]
4. Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans.
Liu G; Wu Q; Liu G; Song X; Zhang J
Cancer Cell Int; 2015; 15():18. PubMed ID: 25745359
[TBL] [Abstract][Full Text] [Related]
5. Group IIa sPLA2 inhibition attenuates NF-κB activity and promotes apoptosis of lung cancer cells.
Yu JA; Kalatardi S; Dohse J; Sadaria MR; Meng X; Fullerton DA; Weyant MJ
Anticancer Res; 2012 Sep; 32(9):3601-7. PubMed ID: 22993297
[TBL] [Abstract][Full Text] [Related]
6. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
7. Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo.
Guo X; Wang W; Hu J; Feng K; Pan Y; Zhang L; Feng Y
Anat Rec (Hoboken); 2012 Dec; 295(12):2114-21. PubMed ID: 22961798
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell phenotype is supported by secretory phospholipase A2 in human lung cancer cells.
Bennett DT; Deng XS; Yu JA; Bell MT; Mauchley DC; Meng X; Reece TB; Fullerton DA; Weyant MJ
Ann Thorac Surg; 2014 Aug; 98(2):439-45; discussion 445-6. PubMed ID: 24928671
[TBL] [Abstract][Full Text] [Related]
9. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
10. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Dong Z; Meller J; Succop P; Wang J; Wikenheiser-Brokamp K; Starnes S; Lu S
Int J Oncol; 2014 Sep; 45(3):978-84. PubMed ID: 24913497
[TBL] [Abstract][Full Text] [Related]
11. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
[TBL] [Abstract][Full Text] [Related]
12. Context-dependent effect of sPLA
Chovatiya GL; Sunkara RR; Roy S; Godbole SR; Waghmare SK
EBioMedicine; 2019 Oct; 48():364-376. PubMed ID: 31521610
[TBL] [Abstract][Full Text] [Related]
13. AMPK Signaling Involvement for the Repression of the IL-1β-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs.
El Hadri K; Denoyelle C; Ravaux L; Viollet B; Foretz M; Friguet B; Rouis M; Raymondjean M
PLoS One; 2015; 10(7):e0132498. PubMed ID: 26162096
[TBL] [Abstract][Full Text] [Related]
14. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
15. Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer.
Wang M; Hao FY; Wang JG; Xiao W
Eur Rev Med Pharmacol Sci; 2014; 18(18):2648-54. PubMed ID: 25317799
[TBL] [Abstract][Full Text] [Related]
16. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Halpern AL; Kohtz PD; White AM; Houk AK; Rehring JF; Hanson L; McCarter MD; Joshi M; Meng X; Fullerton DA; Weyant MJ
Dig Dis Sci; 2021 Mar; 66(3):784-795. PubMed ID: 32277371
[TBL] [Abstract][Full Text] [Related]
17. ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.
Li K; Zhu ZC; Liu YJ; Liu JW; Wang HT; Xiong ZQ; Shen X; Hu ZL; Zheng J
Int J Clin Exp Pathol; 2013; 6(11):2460-7. PubMed ID: 24228108
[TBL] [Abstract][Full Text] [Related]
18. Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa.
Zhang FY; Li RZ; Xu C; Fan XX; Li JX; Meng WY; Wang XR; Liang TL; Guan XX; Pan HD; Liu L; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2022 Jan; 95():153786. PubMed ID: 34785104
[TBL] [Abstract][Full Text] [Related]
19. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
20. sPLA2-IIA Augments Oxidized LDL-Induced MCP-1 Expression in Vitro Through Activation of Akt.
Guo Y; Li B; Xu X; Wu R; Li W
Cell Physiol Biochem; 2015; 37(4):1345-54. PubMed ID: 26488172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
